Association between cannabis use and complications related to Crohn's disease
Crohn's disease is an idiopathic inflammatory process sometimes associated with complications. The anti-inflammatory effect of cannabis in intestinal inflammation has been demonstrated in several experimental models. This study concluded that cannabis use can mitigate many of the well-described complications of Crohn's disease in hospitalized patients. These effects could be caused by the effect of cannabis in the endocannabinoid system.
Crohn's patients who consume cannabis have significantly lower risk of disease-related complications than those who are not treated with cannabis, including a risk of colorectal cancer twice as low, according to a new study.
Crohn's disease is an inflammatory bowel disease whose main symptoms are intense abdominal pain, diarrhea and a sudden drop in weight.
of the previous studies and patient testimonials show that cannabis treatment significantly reduces the symptoms of the disease, probably by activating the cannabinoid receptors located in the gastrointestinal tract.
The study analyzed hospitalization data from 43317 adult patients with Crohn's disease, of whom 615 (1,4%) had taken cannabis.
A comparison of patients using cannabis and the rest of the sample revealed that patients using cannabis also differed by other parameters that could provide an alternative explanation for the results, such as age, sex, race, health insurance, tobacco and alcohol consumption, etc.
The goal is to compare the prevalence of Crohn's disease complications among cannabis users and non-users in patients admitted with a primary diagnosis of Crohn's disease or a primary Crohn's and Crohn's complication diagnosis. a secondary diagnosis of Crohn's disease between 2012 and 2014.
Among matched cohorts, cannabis users were less likely to have the following symptoms
- Active fistulising disease and intra-abdominal abscess 11,5%
for cannabis users versus 15,9% for the rest of the patients.
- Constriction of the intestine - a rate of 11,4% among cannabis users, against 17,5% for the rest of the patients.
- Intestinal blockages: 26,7% of cannabis users, against 38% for the rest of the patients.
- Shorter hospital stay: 4,3 days on average against 5 days.
- Need intravenous feeding: 3,4% for cannabis users, against 5,3% for the rest of the patients.
- The need for blood transfusions: 5% for cannabis users, against 8,2% for the rest.
- The need for surgery to cut the colon:colectomy : 3,7% among cannabis users, against 7,9% for the rest.
Cannabis use can mitigate many of the well-described complications of Crohn's disease in hospitalized patients. These effects could be caused by the effect of cannabis in the endocannabinoid system.